CJC-1295 No DAC + Ipamorelin 10mg
Research Compound Overview
CJC-1295 No DAC + Ipamorelin is a synergistic peptide blend commonly utilized in research focused on growth hormone (GH) and insulin-like growth factor-1 (IGF-1) pathways. By combining two complementary growth hormone secretagogues, this formulation is frequently studied for its potential effects on recovery, tissue repair, body composition, metabolic function, and overall physiological performance.
How It Works
CJC-1295 No DAC is a modified growth hormone-releasing hormone (GHRH) analog that helps stimulate the body’s natural release of growth hormone from the pituitary gland. Unlike CJC-1295 with DAC, the No DAC version has a shorter half-life and is often studied for its ability to more closely mimic the body’s natural pulsatile GH secretion patterns.
Ipamorelin is a selective growth hormone secretagogue that acts on ghrelin receptors to promote growth hormone release while minimizing stimulation of cortisol and prolactin. When combined with CJC-1295 No DAC, researchers often investigate the enhanced and complementary effects of both compounds on growth hormone production.
Research Areas of Interest
- Growth hormone and IGF-1 regulation
- Recovery and tissue regeneration
- Lean muscle development
- Body composition and fat metabolism
- Exercise performance and endurance
- Sleep quality and recovery cycles
- Healthy aging research
Product Specifications
- Peptide Blend: CJC-1295 No DAC + Ipamorelin
- Total Content: 10mg
- Format: Lyophilized (freeze-dried) powder
- Purity: Laboratory tested
- Storage: Store in a cool, dry, dark environment before reconstitution. After reconstitution, refrigerate between 36°F–46°F (2°C–8°C).
Research Use Only
This product is intended exclusively for laboratory research and analytical purposes. It is not intended for human consumption, therapeutic use, diagnosis, or treatment of any disease. Researchers are responsible for ensuring compliance with all applicable regulations and guidelines.




Reviews
There are no reviews yet.